Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulgent Genetics, Inc.FLGT · Entity 2545 | President and COO | September 02, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulgent Genetics, Inc.
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 359,924 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Sale · Disposed 2,127 · Balance 359,924 F1: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025. F2: The shares were sold in multiple transactions at prices ranging from $19.60 to $19.74, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 220,816 |
Reported balance
Holding disclosure · report date 2026-09-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 220,816 F3: Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.
F2: The shares were sold in multiple transactions at prices ranging from $19.60 to $19.74, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F3: Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2022 Filed Jun 2, 2022 20:03 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 668 | $54.54 | $36,433.45 |
DisclosureSEC source: 0001209191-22-033479 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,033 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $54.28 to $54.87, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 19, 2022 Filed May 23, 2022 20:09 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 10,000 | $58.29 | $582,866.00 |
DisclosureSEC source: 0001209191-22-031305 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,701 F1 · price: The shares were sold in multiple transactions at prices ranging from $57.5100 to $59.4350, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:45 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,269 | $53.38 | $67,742.14 |
DisclosureSEC source: 0001209191-22-030078 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,701 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $53.27 to $53.57, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 03, 2022 Filed May 5, 2022 20:46 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 5,904 | $56.69 | $334,697.76 |
DisclosureSEC source: 0001209191-22-027374 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,970 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020. Read SEC document |
| May 01, 2022 Filed May 3, 2022 21:19 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 738 | $54.88 | $40,501.44 |
DisclosureSEC source: 0001209191-22-026813 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,874 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 21:38 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 622 | $63.30 | $39,370.24 |
DisclosureSEC source: 0001209191-22-014778 · doc4.xml · nonDerivative · entry 3 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,612 F3 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019. F4 · price: The shares were sold in multiple transactions at prices ranging from $62.3100 to $64.3650, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:38 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 32,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014778 · doc4.xml · nonDerivative · entry 2 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,234 F2 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after March 1, 2022, and 1/16th of such shares vesting at the end of every three-month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:38 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014778 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,234 F1 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after March 1, 2022, and 1/12th of such shares vesting at the end of every three-month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:07 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 936 | $66.49 | $62,234.64 |
DisclosureSEC source: 0001209191-22-010855 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,234 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 21:37 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 4,029 | $63.15 | $254,431.35 |
DisclosureSEC source: 0001209191-22-007465 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,170 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 01:44 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 504 | $65.34 | $32,931.36 |
DisclosureSEC source: 0001209191-22-007086 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,199 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 22:20 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 636 | $95.42 | $60,685.91 |
DisclosureSEC source: 0001209191-21-067311 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,703 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $94.4300 to $96.5100, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 22:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,214 | $95.50 | $115,939.55 |
DisclosureSEC source: 0001209191-21-065526 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,339 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $95.3400 to $95.6200, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:15 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 5,904 | $88.12 | $520,260.48 |
DisclosureSEC source: 0001209191-21-063148 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,553 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:47 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 738 | $86.79 | $64,051.02 |
DisclosureSEC source: 0001209191-21-062722 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,457 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 21:53 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 622 | $91.25 | $56,759.86 |
DisclosureSEC source: 0001209191-21-054296 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,195 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $89.43 to $92.41, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 22:03 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,223 | $95.12 | $116,335.06 |
DisclosureSEC source: 0001209191-21-052313 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,817 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $94.6257 to $96.0400, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 23:28 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 23,615 | $100.46 | $2,372,362.90 |
DisclosureSEC source: 0001209191-21-050054 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,040 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020. Read SEC document |
| August 01, 2021 Filed Aug 4, 2021 00:17 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 739 | $92.25 | $68,172.75 |
DisclosureSEC source: 0001209191-21-049491 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,655 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:45 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 647 | $73.46 | $47,527.07 |
DisclosureSEC source: 0001209191-21-037241 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,394 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $72.95 to $73.78, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 25, 2021 Filed May 27, 2021 22:58 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 2,000 | $72.21 | $144,412.00 |
DisclosureSEC source: 0001209191-21-036334 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,041 F1 · price: The shares were sold in multiple transactions at prices ranging from $72.20 to $72.24, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 20, 2021 Filed May 21, 2021 00:50 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,000 | $74.48 | $74,480.00 |
DisclosureSEC source: 0001209191-21-034718 · doc4.xml · nonDerivative · entry 2 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,041 Read SEC document |
| May 18, 2021 Filed May 21, 2021 00:50 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 931 | $70.71 | $65,831.20 |
DisclosureSEC source: 0001209191-21-034718 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,041 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $69.61 to $71.05, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 01, 2021 Filed May 3, 2021 20:54 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 504 | $77.02 | $38,818.08 |
DisclosureSEC source: 0001209191-21-029488 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,972 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:09 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 3,000 | $104.10 | $312,300.00 |
DisclosureSEC source: 0001209191-21-021425 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,476 Read SEC document |
| March 11, 2021 Filed Feb 9, 2024 23:09 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 5,700 | $101.66 | $579,479.67 |
DisclosureSEC source: 0000950170-24-013414 · ownership.xml · nonDerivative · entry 2 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,124 F3 · shares: The sale of the shares occured in the fiscal year ended December 31, 2021, but the filing of the Form 4 was inadvertently missed during that period. F4 · price: The shares were sold in multiple transactions at prices ranging from $100.28 to $104.09, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 10, 2021 Filed Feb 9, 2024 23:09 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 4,300 | $108.22 | $465,327.08 |
DisclosureSEC source: 0000950170-24-013414 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,824 F1 · shares: The sale of the shares occured in the fiscal year ended December 31, 2021, but the filing of the Form 4 was inadvertently missed during that period. F2 · price: The shares were sold in multiple transactions at prices ranging from $103.92 to $112.00, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission (the "SEC") staff, Fulgent Genetics, Inc. (the "Issuer") or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 22:13 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 62,000 | $102.65 | $6,364,219.40 |
DisclosureSEC source: 0001209191-21-019834 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,476 F1 · price: The shares were sold in multiple transactions at prices ranging from $100.54 to $104.50, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 21:10 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 403 | $101.26 | $40,807.78 |
DisclosureSEC source: 0001209191-21-015862 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,476 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019. Read SEC document |
| February 15, 2021 Filed Feb 16, 2021 23:12 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 806 | $161.09 | $129,838.54 |
DisclosureSEC source: 0001209191-21-010935 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,879 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:59 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 504 | $137.91 | $69,506.64 |
DisclosureSEC source: 0001209191-21-007410 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408,685 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:23 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GiftCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-063786 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,189 F1 · shares: Reflects shares transferred as a gift to the James and Karena Xie Family Foundation (the "Foundation"). The Reporting Person disclaims beneficial ownership over the shares held by the Foundation. Read SEC document |
| December 02, 2020 Filed Dec 2, 2020 23:03 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,000 | $46.00 | $46,000.00 |
DisclosureSEC source: 0001209191-20-061261 · doc4.xml · nonDerivative · entry 4 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,689 F4 · price: The shares were sold in multiple transactions at a single price $46.00. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 23:03 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,000 | $45.16 | $45,160.00 |
DisclosureSEC source: 0001209191-20-061261 · doc4.xml · nonDerivative · entry 3 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,689 Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:03 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 396 | $43.59 | $17,261.72 |
DisclosureSEC source: 0001209191-20-061261 · doc4.xml · nonDerivative · entry 2 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433,689 F2 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019. F3 · price: The shares were sold in multiple transactions at prices ranging from $43.29 to $43.95, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:03 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 3,000 | $43.17 | $129,500.10 |
DisclosureSEC source: 0001209191-20-061261 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,085 F1 · price: The shares were sold in multiple transactions at prices ranging from $42.50 to $44.50, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 22:24 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 6,000 | $44.08 | $264,480.00 |
DisclosureSEC source: 0001209191-20-060280 · doc4.xml · nonDerivative · entry 2 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,085 F2 · price: The shares were sold in multiple transactions at prices ranging from $42.50 to $45.00, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 22:24 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,000 | $42.50 | $42,500.00 |
DisclosureSEC source: 0001209191-20-060280 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443,085 F1 · price: The shares were sold in multiple transactions at a single price $42.50. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 01:15 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 3,000 | $44.83 | $134,499.90 |
DisclosureSEC source: 0001209191-20-059547 · doc4.xml · nonDerivative · entry 3 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,085 F4 · price: The shares were sold in multiple transactions at prices ranging from $44.50 to $45.00, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 01:15 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 500 | $44.61 | $22,303.00 |
DisclosureSEC source: 0001209191-20-059547 · doc4.xml · nonDerivative · entry 2 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447,085 F3 · price: The shares were sold in multiple transactions at prices ranging from $44.59 to $44.67, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 01:15 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 3,206 | $45.45 | $145,708.85 |
DisclosureSEC source: 0001209191-20-059547 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447,585 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $45.2512 to $45.56, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 01, 2020 Filed Nov 3, 2020 21:22 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon stock | 504 | $32.53 | $16,395.12 |
DisclosureSEC source: 0001209191-20-056615 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,791 F1 · kind: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 20:43 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | OtherCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-050295 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,736 F1 · kind: The transfer was made without the receipt of consideration to a blind trust. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. Read SEC document |
| August 28, 2020 Filed Sep 23, 2020 23:35 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 441 | $30.82 | $13,590.96 |
DisclosureSEC source: 0001209191-20-051720 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,295 F1 · shares: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $30.54 to $31.02, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 03, 2020 Filed Aug 6, 2020 00:57 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,976 | $27.86 | $55,054.92 |
DisclosureSEC source: 0001209191-20-045395 · doc4.xml · nonDerivative · entry 2 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,736 F2 · kind: The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. F3 · price: The shares were sold in multiple transactions at prices ranging from $27.56 to $28.46, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 03, 2020 Filed Aug 6, 2020 00:57 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-045395 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 603,712 F1 · shares: Reflects an award of restricted stock units relating to 200,000 shares of the Issuer's common stock. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after August 15, 2020, and 1/16th of such shares vesting every three months over the remaining 36 months, subject to the reporting person's continued service for Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.